News & Updates
RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) – – RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – – RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards – Excerpt from the Press Release: SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE)…
Read More
Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months Excerpt from the Press Release: MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company…
Read More
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
– With no dose-limiting toxicities observed, treatment of second dose cohort to begin Excerpt from the Press Release: SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it…
Read More
– Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study – Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 13, 2023 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA. The study will…
Read More
Preclinical findings support the advancement of BBI-825, a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), as a differentiated treatment approach for ecDNA-enabled oncogene or resistance gene amplified cancers, including resistance associated with treatment of KRASG12C mutant colorectal cancer (CRC) A second poster presentation reveals insight into the intrinsic genomic plasticity of extrachromosomal DNA…
Read More
– Results showing significant reductions in liver fat content and body weight, no loss of lean muscle mass, and improvement in key markers of metabolism and inflammation published in The Lancet Gastroenterology & Hepatology – – HU6 was well tolerated at once-daily oral doses with adverse events mainly mild or moderate in severity Excerpt from…
Read More
The Ontario Institute for Cancer Research has new funding opportunities: “OICR’s Clinical Translation Pathway (CTP) supports practice-changing research in biomarkers and therapeutics that will advance early detection and intervention research and have a clear path to the clinic and clinical impact. OICR is currently inviting applications for one of the CTP funding streams, Pre-Clinical Acceleration Team…
Read More
PATHFINDER Results Support Feasibility of Multi-Cancer Early Detection (MCED) Testing in Clinical Practice of Eligible Patients Accuracy of Cancer Signal Origin Prediction of MCED Testing Enabled Targeted Diagnostic Evaluations; Majority of Participants Achieved Diagnostic Resolution in Less Than Three Months Adding MCED Testing to Standard of Care Screening More Than Doubled the Number of New…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?